NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
27 hedge funds and large institutions have $1.08M invested in NeuBase Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
23% less funds holding
Funds holding: 35 → 27 (-8)
37% less capital invested
Capital invested by funds: $1.72M → $1.08M (-$635K)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$547K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$22.8K |
| 3 |
Renaissance Technologies
New York
|
+$13.1K |
| 4 |
JP Morgan Chase
New York
|
+$1.78K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$932 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$117K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$25K |
| 3 |
WPW
Waldron Private Wealth
Bridgeville,
Pennsylvania
|
-$14.7K |
| 4 |
State Street
Boston,
Massachusetts
|
-$12.7K |
| 5 |
BlackRock
New York
|
-$11.1K |
NBSE Hedge Fund Activity: Q2 2023 in Review
27 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2023, worth a combined $1.08M — down 37% from $1.72M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of NBSE and 6 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 3 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $547K. The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $117K sold.
- 27 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2023, down from 35 in Q1 2023.
- Funds reported $1.08M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2023, down 37% quarter-over-quarter.
- 6 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2023 and 14 closed out, a net change of -8 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2023 was Armistice Capital, an estimated $547K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2023 was Polar Asset Management Partners, an estimated $117K sold.
Based on aggregated 13F filings for Q2 2023.